En Es
Categories

Industry News

New AI Model Identifies Women Facing Future Risk of Breast Cancer

By Medimaging International staff writers
07 Jan 2020

IllustrationResearchers from the Karolinska Institute (Stockholm, Sweden) have developed a sophisticated type of artificial intelligence (AI) which can outperform existing models at predicting which women are at future risk of breast cancer.

Most existing breast cancer screening programs are based on mammography at similar time intervals -- typically, annually or every two years -- for all women. This "one size fits all" approach is not optimized for cancer detection on an individual level and may hamper the effectiveness of screening programs. High breast density, or a greater amount of glandular and connective tissue compared to fat, is considered a risk factor for cancer. While density may be incorporated into risk assessment, current prediction models may fail to fully take advantage of all the rich information found in mammograms. This information has the potential to identify women who would benefit from additional screening with MRI.

The Swedish researchers developed a risk model that relies on a deep neural network, a type of AI that can extract vast amounts of information from mammographic images. It offers inherent advantages over other methods such as visual assessment of mammographic density by the radiologist that may be unable to capture all risk-relevant information in the image. The new model was developed and trained on mammograms from cases diagnosed between 2008 and 2012 and then studied on more than 2,000 women ages 40 to 74 who had undergone mammography in the Karolinska University Hospital system. Of the 2,283 women in the study, 278 were later diagnosed with breast cancer.

The deep neural network showed a higher risk association for breast cancer as compared to the best mammographic density model. The false negative rate -- the rate at which women who were not categorized as high-risk were later diagnosed with breast cancer -- was lower for the deep neural network than for the best mammographic density model. The study findings support a future role for AI in breast cancer risk assessment. As an additional benefit, the AI approach can continually be improved with exposure to more high-quality data sets.

"The deep neural network overall was better than density-based models," said study lead author Karin Dembrower, M.D., breast radiologist and Ph.D. candidate from the Karolinska Institute in Stockholm, Sweden. "And it did not have the same bias as the density-based model. Its predictive accuracy was not negatively affected by more aggressive cancer subtypes."

Related Links:
Karolinska Institute



E-mail Print
FaceBook Twitter Google+ Linked in

Additional news

03 Aug 2020
Siemens to Acquire Varian Medical to Create Comprehensive Cancer Portfolio
Siemens Healthineers (Erlangen, Germany) has entered into an agreement to acquire Varian Medical Systems, Inc. (Palo Alto, CA, USA) that will lead to the creation of a global leader in healthcare with a comprehensive portfolio to fight cancer.
Read More
17 Jul 2020
Awareness Technology Announces ChemWell RPR Analyzer - The Most Significant Innovation in Syphilis Testing in Last 30 Years
Awareness Technology, Inc. (Palm City, FL, USA) has announced the most significant innovation in syphilis testing in the last 30 years with the launch of the ChemWell RPR automated nontreponemal analyzer for the detection of syphilis.
Read More
23 Jun 2020
Omnia Health Live Unites Global Healthcare Community Through New Virtual Experience
Omnia Health Live, a virtual healthcare event, has brought the global healthcare community together on a scale never seen before through a new experience delivered entirely online.
Read More
12 Jun 2020
Global Magnetic Resonance Imaging (MRI) Market to be driven by Advancements in Medical Diagnostics
The global magnetic resonance imaging (MRI) market was valued at USD 5.90 billion in 2017 and is projected to register a CAGR of 5.2% from 2018 to 2026, driven by increased demand for MRI equipment across the world due to a substantial rise in incidence of disorders related to spine, neurology, orthopedic, cardiovascular, head and neck, and abdominal and prostate.
Read More
30 May 2020
MEDICAL FAIR ASIA 2020 Set to Take Place in Singapore from 9-11 December 2020
MEDICAL FAIR ASIA 2020 is set to take place in Singapore from 9-11 December 2020 at Marina Bay Sands, with the exhibition featuring the latest medical technology and innovations, and healthcare equipment and supplies.
Read More
20 Apr 2020
Nova's Stat EMS Basic Blood Testing System Launched in CE Mark Countries
Nova Biomedical (Waltham, MA, USA) has launched the Stat EMS Basic blood testing system for ambulance and emergency care in CE mark countries. Stat EMS Basic measures fingerstick capillary lactate, glucose, ketone, hemoglobin, and hematocrit in six to 40 seconds with laboratory-quality results.
Read More
20 Apr 2020
Nova's Stat Profile Prime Plus Blood Gas Analyzer Receives FDA Clearance for POC Use
Nova Biomedical (Waltham, MA, USA) has secured clearance from the US Food and Drug Administration (FDA) for its Stat Profile Prime Plus critical care blood gas analyzer for point-of-care (POC) use.
Read More
17 Apr 2020
ECR 2020 to Go Ahead as Online Congress on July 15-19, 2020
In view of the ongoing spread of COVID-19 across the world and its growing global impact, the board of directors of the European Society of Radiology (Vienna) has decided not to hold an onsite European Congress of Radiology (ECR) in 2020. Instead, ECR 2020 will go ahead as an online congress to ensure a safe experience for its members, partners, staff and the general public.
Read More
08 Apr 2020
Nova Biomedical Adds PT/INR Test to Allegro Analyzer for POC Testing
Nova Biomedical (Waltham, MA, USA) has added PT/INR testing for its Allegro capillary blood analyzer for point-of-care (POC) testing in primary care settings. With the ability to test for clotting disorders and monitor the effectiveness of blood-thinning medications, the Allegro and its StatStrip-A companion meter provide 18 clinically important tests to help physicians make therapeutic decisions and adjustments at the POC.
Read More
Copyright © 2000-2020 TradeMed.com. All rights reserved. | Terms And Conditions